Holly Peay

List of Publications by Year
in descending order

41	983	430442 18	454577 30
papers	citations	h-index	g-index

43	43	43	1298
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recommendations for analytical antiretroviral treatment interruptions in HIV research trialsâ€"report of a consensus meeting. Lancet HIV,the, 2019, 6, e259-e268.	2.1	139
2	A Community-Engaged Approach to Quantifying Caregiver Preferences for the Benefits and Risks of Emerging Therapies for Duchenne Muscular Dystrophy. Clinical Therapeutics, 2014, 36, 624-637.	1.1	96
3	Practical Considerations in Using Online Modified-Delphi Approaches to Engage Patients and Other Stakeholders in Clinical Practice Guideline Development. Patient, 2020, 13, 11-21.	1.1	62
4	Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. Journal of Medical Ethics, 2018, 44, medethics-2017-104433.	1.0	51
5	Caregiver Preferences for Emerging Duchenne Muscular Dystrophy Treatments: A Comparison of Best-Worst Scaling and Conjoint Analysis. Patient, 2015, 8, 19-27.	1.1	44
6	Patientâ€centered benefitâ€"risk assessment in duchenne muscular dystrophy. Muscle and Nerve, 2017, 55, 626-634.	1.0	38
7	Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne/Becker muscular dystrophy. Clinical Trials, 2014, 11, 77-85.	0.7	36
8	What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. Journal of Virus Eradication, 2015, 1, 51-53.	0.3	34
9	Prioritizing Parental Worry Associated with Duchenne Muscular Dystrophy Using Bestâ€Worst Scaling. Journal of Genetic Counseling, 2016, 25, 305-313.	0.9	31
10	Mothersâ€™ psychological adaptation to Duchenne/Becker muscular dystrophy. European Journal of Human Genetics, 2016, 24, 633-637.	1.4	31
11	What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. Journal of Virus Eradication, 2015, 1, 51-53.	0.3	31
12	Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders. Clinical Trials, 2018, 15, 139-148.	0.7	30
13	Early Check: translational science at the intersection of public health and newborn screening. BMC Pediatrics, 2019, 19, 238.	0.7	26
14	Measuring quality of life in muscular dystrophy. Neurology, 2015, 84, 1034-1042.	1.5	24
15	Going off antiretroviral treatment in a closely monitored HIV â€œcureâ€•trial: longitudinal assessments of acutely diagnosed trial participants and decliners. Journal of the International AIDS Society, 2019, 22, e25260.	1.2	23
16	Expert Evaluation of Strategies to Modernize Newborn Screening in the United States. JAMA Network Open, 2021, 4, e2140998.	2.8	23
17	Using an Online, Modified Delphi Approach to Engage Patients and Caregivers in Determining the Patient-Centeredness of Duchenne Muscular Dystrophy Care Considerations. Medical Decision Making, 2019, 39, 1019-1031.	1.2	22
18	Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents. PLoS ONE, 2019, 14, e0213649.	1.1	21

#	Article	IF	Citations
19	Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a bestâ€“worst scaling experiment in caregivers and adult patients. Orphanet Journal of Rare Diseases, 2019, 14, 102.	1.2	20
20	Practical Considerations for Using Online Methods to Engage Patients in Guideline Development. Patient, 2018, 11, 155-166.	1.1	19
21	Parent Experiences of Sanfilippo Syndrome Impact and Unmet Treatment Needs: A Qualitative Assessment. Neurology and Therapy, 2021, 10, 197-212.	1.4	19
22	â€œWatching time tick byâ€¦â€• Decision making for Duchenne muscular dystrophy trials. Contemporary Clinical Trials, 2016, 46, 1-6.	0.8	18
23	Engaging Patients and Caregivers Managing Rare Diseases to Improve the Methods of Clinical Guideline Development: A Research Protocol. JMIR Research Protocols, 2017, 6, e57.	0.5	15
24	â€œIf He Has it, We Know What to Doâ€• Parent Perspectives on Familial Risk for Autism Spectrum Disorder. Journal of Pediatric Psychology, 2020, 45, 121-130.	1.1	14
25	Application of a framework to guide genetic testing communication across clinical indications. Genome Medicine, 2021, 13, 71.	3.6	14
26	Preparing newborn screening for the future: a collaborative stakeholder engagement exploring challenges and opportunities to modernizing the newborn screening system. BMC Pediatrics, 2022, 22, 90.	0.7	14
27	How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches. AIDS and Behavior, 2019, 23, 2146-2154.	1.4	11
28	Fragile X syndrome clinical trials: exploring parental decisionâ€making. Journal of Intellectual Disability Research, 2019, 63, 926-935.	1.2	10
29	Recognition and management of motor delay and muscle weakness in children. American Family Physician, 2015, 91, 38-44.	0.1	8
30	An Evidenceâ€Based, Communityâ€Engaged Approach to Develop an Interactive Deliberation Tool for Pediatric Neuromuscular Trials. Journal of Genetic Counseling, 2018, 27, 416-425.	0.9	7
31	Patientsâ€™ and caregiversâ€™ maximum acceptable risk of death for nonâ€curative gene therapy to treat Duchenne muscular dystrophy. Molecular Genetics & Genomic Medicine, 2021, 9, e1664.	0.6	7
32	Psychosocial Needs and Facilitators of Mothers Caring for Children with Duchenne/Becker Muscular Dystrophy. Journal of Genetic Counseling, 2018, 27, 197-203.	0.9	6
33	Cohorts as collections of bodies and communities of persons: insights from the SEARCH010/RV254 research cohort. International Health, 2020, 12, 584-590.	0.8	6
34	The Ethics of Predicting Autism Spectrum Disorder in Infancy. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 942-945.	0.3	6
35	Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy. International Journal of Neonatal Screening, 2022, 8, 12.	1.2	6
36	Parent clinical trial priorities for fragile X syndrome: a bestâ€“worst scaling. European Journal of Human Genetics, 2021, 29, 1245-1251.	1.4	4

#	Article	IF	Citations
37	Recommendations from Thai stakeholders about protecting HIV remission (â€˜cureâ€™) trial participants: report from a participatory workshop. International Health, 2020, 12, 567-574.	0.8	4
38	Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria. AIDS and Behavior, 2022, 26, 1504-1516.	1.4	4
39	Caregivers' assessment of meaningful and relevant clinical outcome assessments for Sanfilippo syndrome. Journal of Patient-Reported Outcomes, 2022, 6, 40.	0.9	3
40	Meaningful treatment outcomes for Sanfilippo syndrome: A study of caregiver preferences and prioritization. Molecular Genetics and Metabolism, 2019, 126, S112-S113.	0.5	2
41	The RAND/PPMD Patient-Centeredness Method: a novel online approach to engaging patients and their representatives in guideline development. European Journal for Person Centered Healthcare, 2019, 7, 470-475.	0.3	2